INOVIO PHARMACEUTICALS, INC.

INO is the ticker symbol for INOVIO PHARMACEUTICALS, INC., a publicly traded US company.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Key metrics include a return on equity of -324.4%, a debt-to-equity ratio of 7.20.

The company reports trailing twelve-month revenue of $1.53M and net loss of $19.68M.

FINOTAUR aggregates real-time and fundamental data on INO to help traders and investors make informed decisions. Track INO in your trading journal alongside other positions for a unified view of your portfolio.